BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29681454)

  • 21. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
    J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging roles of Nrf2 signal in non-small cell lung cancer.
    Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
    J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A catalogue of somatic NRF2 gain-of-function mutations in cancer.
    Kerins MJ; Ooi A
    Sci Rep; 2018 Aug; 8(1):12846. PubMed ID: 30150714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
    Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
    Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
    Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
    J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
    Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
    Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
    Zhang B; Ma Z; Tan B; Lin N
    Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1/Nrf2 pathway.
    Heyninck K; Sabbe L; Chirumamilla CS; Szarc Vel Szic K; Vander Veken P; Lemmens KJA; Lahtela-Kakkonen M; Naulaerts S; Op de Beeck K; Laukens K; Van Camp G; Weseler AR; Bast A; Haenen GRMM; Haegeman G; Vanden Berghe W
    Biochem Pharmacol; 2016 Jun; 109():48-61. PubMed ID: 27045103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.